S7326
SB 657510
≥98% (HPLC)
别名:
2-Bromo-N-[4-chloro-3-[[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]-4,5-dimethoxy-benzenesulfonamide, SB-657510
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C19H22BrClN2O5S
化学文摘社编号:
分子量:
505.81
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to off-white
solubility
DMSO: ≥30 mg/mL
originator
GlaxoSmithKline
storage temp.
room temp
SMILES string
COc1cc(Br)c(cc1OC)S(=O)(=O)Nc2ccc(Cl)c(O[C@@H]3CCN(C)C3)c2
InChI
1S/C19H22BrClN2O5S/c1-23-7-6-13(11-23)28-16-8-12(4-5-15(16)21)22-29(24,25)19-10-18(27-3)17(26-2)9-14(19)20/h4-5,8-10,13,22H,6-7,11H2,1-3H3/t13-/m1/s1
InChI key
KQCZCINJGIRLCD-CYBMUJFWSA-N
Application
SB 657510 may be used to study the urotensin II receptor-mediated signaling.
Biochem/physiol Actions
SB 657510 is a potent and selective urotensin-II (UT) receptor antagonist.
SB 657510 slows development of diabetes-associated atherosclerosis in mouse model of diabetes.1
SB-657510 is a selective urotensin-II (UT) receptor antagonist. Human urotensin-II (hU-II) is proposed to play a significant role in cardiorenal and metabolic disease states, including heart failure, atherosclerosis, hypertension.
Features and Benefits
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable